NCT06066723View on ClinicalTrials.gov

19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease

RecruitingOBSERVATIONAL
Enrollment

15

Participants

Timeline

Start Date

June 16, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Cystic Fibrosis in Children
Interventions
COMBINATION_PRODUCT

19F MRI

Inhalation of a biologically inert contrast gas, perfluoropropane, combined with 19F-tuned MRI with image acquisition at breath-hold and during tidal breathing.

Trial Locations (1)

27514

RECRUITING

University of North Carolina at Chapel Hill, Chapel Hill

All Listed Sponsors
collaborator

Cystic Fibrosis Foundation

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of North Carolina, Chapel Hill

OTHER

NCT06066723 - 19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease | Biotech Hunter | Biotech Hunter